Danish anti-cancer drugs by the US government approved

Danish biopharmaceutical company Genmab newly developed anti-cancer drugs Darzalex approved by the US Food and Drug Administration. The drug is mainly suitable for repeated treatment ineffective bone marrow cancer, has been approved for use in the case of the three treatment ineffective. Currently, the company and its partners are applying the drug used in the initial treatment. The drug is eligible for US government-approved news boosted Genmab company fiscal year 2015 performance expectations, the company is now forecast sales this year at around 1.1 billion Danish kroner, compared with the previous increase of 300 million Danish kroner, operating profit is expected at 6.25-7 billion Danish between the krone, and it had expected to 3.25-4 billion Danish kroner.

( Bolise Co., Ltd. www.chemicalspharm.com )